Litcius/Paper detail

Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials

Sunil V. Badve, Anika Bilal, Matthew M.Y. Lee, Naveed Sattar, Hertzel C. Gerstein, Christian T. Ruff, John J.V. McMurray, Peter Rossing, George Bakris, Kenneth W. Mahaffey, Johannes F.E. Mann, Helen M. Colhoun, Katherine R Tuttle, Richard E. Pratley, Vlado Perkovic

2024The Lancet Diabetes & Endocrinology270 citationsDOIOpen Access PDF

Topics & Concepts

MedicineMeta-analysisGlucagon-like peptide 1 receptorRandomized controlled trialMEDLINESemaglutideInternal medicineType 2 diabetesDiseaseDiabetes mellitusIntensive care medicineLiraglutideAgonistEndocrinologyReceptorLawPolitical scienceDiabetes Treatment and ManagementChronic Kidney Disease and DiabetesHyperglycemia and glycemic control in critically ill and hospitalized patients
Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials | Litcius